NEW YORK, Feb. 9, 2016 /PRNewswire/ -- Spheryx, Inc. announced today that their journal article entitled “Holographic Characterization of Protein Aggregates”, is now available on-line in the prestigious, peer-reviewed Journal of Pharmaceutical Sciences and will be available in print in an upcoming volume of the Journal. Dr. Laura A. Philips, CEO and Dr. David B. Ruffner, Director of Analytical Services are two of the co-authors of the article. Other authors include Prof. David G. Grier and Prof. Michael D. Ward professors of physics and chemistry at New York University. Prof. Grier is also a co-founder of Spheryx, and Chair of the Spheryx Scientific Advisory Board.
The article describes the application of holographic video microscopy to the detection of protein aggregates, a safety concern for the patients of protein-based biologic pharmaceuticals. The technology is compared, in the article, to other technologies currently used in the field. Dr. Philips stated “The publication of this article is an opportunity to present the power of holographic characterization to the pharmaceutical development community where the technology may find applications in R&D and manufacturing biologic pharmaceuticals.” Prof. Grier added, “It is gratifying to see that technology based in fundamental physics can find important applications to real world problems.” The article can be found at: http://dx.doi.org/10.1016/j.xphs.2015.12.018
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization of colloidal materials. Spheryx’s breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials’ characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information please visit the company’s website at http://www.spheryx.solutions/
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially. These risks and uncertainties include, among others: the results, timing and costs of our studies; our ability to obtain future funding on acceptable terms; the possible impairment of, or inability to obtain intellectual property rights; and innovation by our competitors.
Contact:
Laura Philips, CEO
lphilips@spheryx.solutions
607-738-0100
Logo - http://photos.prnewswire.com/prnh/20160208/330974LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spheryx-technology-published-in-the-journal-of-pharmaceutical-sciences-300217053.html
SOURCE Spheryx, Inc.
